Licensing status

Publication and contact information

Endocrine/metabolic disease


Dipeptidyl peptidase-4 (DPP-4; CD26)

Mouse studies suggest a DPP-4 peptide vaccine could help treat type 2 diabetes. DPP-4 increases degradation of glucagon-like peptide-1 (GLP-1), which normally enhances insulin secretion and insulin sensitivity. In mice, a DPP-4 vaccine candidate was shown to induce DPP-4-specific antibody titers and decrease DPP-4 in plasma and increase GLP-1 levels compared with the vaccine's protein carrier alone. In two mouse models of diabetes or in mice fed a high-fat diet, the vaccine delayed diabetes onset, decreased postprandial glucose levels and increased insulin sensitivity. Next steps could include testing the long-term effects of the vaccine and evaluating it in additional diabetes models.

SciBX 7(16); doi:10.1038/scibx.2014.460
Published online April 24, 2014

Patent and licensing status unavailable

Pang, Z. et al. Proc. Natl. Acad. Sci. USA; published online March 17, 2014;
Contact: Hironori Nakagami, Osaka University, Osaka, Japan